Biomerica to Participate in Upcoming Investor Conferences
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Biomerica, Inc. (Nasdaq: BMRA) announced its participation in the upcoming Truist Life Sciences Series and LD Micro Invitational XI investor conferences. CEO Zack Irani will present virtually at the LD Micro event on June 8 at 2:30 PM ET. Additionally, Biomerica will conduct one-on-one investor meetings on June 10 as part of the Truist series. Biomerica focuses on developing advanced diagnostic and therapeutic products, particularly for gastrointestinal and inflammatory diseases, aiming to improve health outcomes and reduce healthcare costs.
Details
News Market Reaction – BMRA
The recorded move for BMRA in the trading session of this news was +1.65%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
IRVINE, Calif., June 04, 2021 (GLOBE NEWSWIRE) -- Biomerica, Inc. (Nasdaq: BMRA), a global provider of advanced medical products, today announced that it will be participating in two upcoming investor conferences: the Truist Life Sciences Series and LD Micro Invitational XI event.
Zack Irani, Chief Executive Officer of Biomerica will be presenting virtually at the LD Micro Invitational XI event on Tuesday, June 8th at 2:30 PM ET. Register to access the LD Micro Invitational XI here.
Biomerica will also be conducting one-on-one investor meetings as part of the Truist Life Science Series on Thursday, June 10th.
About Biomerica (NASDAQ: BMRA)
Biomerica, Inc. (www.biomerica.com) is a global biomedical technology company that develops, patents, manufactures and markets advanced diagnostic and therapeutic products used at the point of care (in home and in physicians' offices) and in hospital/clinical laboratories for detection and/or treatment of medical conditions and diseases. The Company's products are designed to enhance the health and well-being of people, while reducing total healthcare costs. Biomerica’s primarily focus is on gastrointestinal and inflammatory diseases where the Company has multiple diagnostic and therapeutic products in development.
Corporate Contact:
John Nesbett /Jennifer Belodeau
IMS Investor Relations
203.972.9200
jnesbett@institutionalms.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.